market consultant

Nov 28, 2017

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...

Nov 15, 2017

One of the top five risks for human health includes poor air quality, while the others are blood pressure, smoking tobacco, diabetes, and obesity. The poor air quality has contributed to around 8% of deaths around the world, according to a 2015 statistic and long-term exposure has created health hazard risks such as...